PROLOR Biotech Inc  

(Public, NYSEMKT:PBTH)   Watch this stock  
Find more results for NYSEAMEX:PBTH
8.23
Aug 29 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap 525.53M
P/E     -
Div/yield     -
EPS -1.36
Shares 63.85M
Beta     -
Inst. own 7%

Key stats and ratios

Q2 (Jun '13) 2012
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -136.32% -71.74%
Return on average equity -151.72% -79.92%
Employees 25 -
CDP Score - -

Address

202 N CARSON ST
CARSON CITY, NV 89701
United States - Map

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Prolor Biotech Inc (Prolor) is a development-stage biopharmaceutical company, utilizing technology to develop longer-acting, versions of therapeutic proteins. The Company is using the carboxyl terminal peptide (CTP) technology to develop new versions of certain therapeutic proteins that have longer life spans than therapeutic proteins without CTP. Human Growth Hormone is used for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone. Factor IX is offered to Hemophilia B patients by Pfizer, under the brand name BeneFIX. As of December 31, 2012, the Company´┐Żs product development program is focused on extending the life span of Human Growth Hormone (hGH), Factor IX, Anti-Obesity Peptide Oxyntomodulin, Factor VIIa, Interferon B and Erythropoietin (EPO) and Atherosclerosis and rheumatoid arthritis long-acting therapies.